Ocugen’s (OCGN) “Buy” Rating Reiterated at Chardan Capital

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating reiterated by Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $6.00 price objective on the stock.

Separately, HC Wainwright boosted their target price on Ocugen from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday.

Ocugen Price Performance

Shares of NASDAQ OCGN opened at $0.66 on Thursday. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average price is $0.78 and its two-hundred day moving average price is $0.98. The company has a market cap of $192.27 million, a PE ratio of -3.67 and a beta of 3.82. Ocugen has a twelve month low of $0.57 and a twelve month high of $2.11.

Institutional Trading of Ocugen

Several hedge funds and other institutional investors have recently modified their holdings of OCGN. Virtu Financial LLC acquired a new stake in Ocugen during the fourth quarter worth approximately $32,000. SBI Securities Co. Ltd. acquired a new stake in Ocugen during the 4th quarter worth approximately $40,000. SG Americas Securities LLC bought a new stake in Ocugen in the 3rd quarter valued at $87,000. MetLife Investment Management LLC grew its holdings in Ocugen by 36.4% in the 3rd quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock valued at $89,000 after buying an additional 23,877 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC bought a new position in Ocugen during the 3rd quarter worth $90,000. Institutional investors own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.